Lupus & antiphospholipid syndrome
Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS ( Vo closporin in R eal L ife S etting S tudy) experience
Authors' conclusion
VCL may provide a valuable therapeutic option in LN management, achieving early 24 h-proteinuria response consistent with clinical trial data.
Study context
- Population
- Patients with biopsy-proven LN, tertiary Rheumatology and Nephrology Italian Centres, November 2023 to April 2025; excluded uncontrolled arterial hypertension and eGFR < 30 ml/min/1.73 m²
- Participants
- 42 patients14 centres
- Outcome
- CRR or PRR
Methodological detailsobservational, clinical-practice-based, nationwide multicentre
- Observational
- Clinical-practice-based
- Nationwide multicentre
Main finding
As reported in the abstract
Complete renal response (CRR) or partial renal response (PRR) at 6 weeks
31.5%
CRR or PRR at 12 weeks
68.9%
CRR or PRR at 24 weeks
83.3%
CRR or PRR at 48 weeks
91.6%
Observational data: associations, not effects.
Further findings
24-h proteinuria decrease · 6 weeks and all subsequent time points
- Significant decrease at 6 weeks
- P = 0.006
- Significant at all subsequent time points
eGFR decrease (mild)
- At 6 weeks
- P = 0.008
- At 24 weeks
- P = 0.01
- Not at 48 weeks
Anti-dsDNA positivity decrease
- At 6 weeks
- P = 0.0016
- At 12 weeks
- P = 0.0009
SLEDAI-2K decrease
- After 24 weeks
- P = 0.008
- After 48 weeks
- P = 0.05
Original publication
Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS ( Vo closporin in R eal L ife S etting S tudy) experience. Rheumatology (Oxford). Published 12 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →